Prostate Cancer

...Paola Muti, an epidemiologist from the Italian National Cancer Institute-Rome, the epidemiological evidence on the role of estrogens and androgens in breast cancer development;Dr.

Rogan, University of Nebraska Medical Center, the metabolism of estrogens to reactive forms in the human breast and the differences between women who have breast cancer and those who do not.

This research identifies biomarkers that could be used for early detection of cancer risk;Dr.

Jankowiak, Kansas State University, biomonitoring techniques he has developed for assessing breast and Dhrubajyoti Chakravarti, University of Nebraska Medical Center, and Joseph Guttenplan, College of Dentistry, New York University, how estrogen metabolites induce mutations, which are key events in initiating cancer;Drs.

Jose Russo, Fox Chase Cancer Center, and Thomas Sutter, Feinstone Center for Genomic Research, University of Memphis, the role of estrogens in human breast cancer, as demonstrated in cultured human breast cells, and how mutations accumulate during estrogen-induced transformation of breast cells to cancer cells.

Email this article Join Our Forum and Write Your Opinion Print RSS Feed This category only Latest Articles Delay in Surgery Decreases Survival for Bladder Cancer Patients Researchers Study Exercise To Curb 'Chemo Brain' Research Identifies Specific Teenage and Young Adult Cancers and Poin...

...04, 2006 Study 1: A death receptor-mediated pathway helps doxazosin boost apoptosis in prostate cells.

"Quinazoline-based alpha1-adrenoceptor antagonists such as doxazosin and terazosin have been previously shown to induce apoptosis in In this study, the molecular events initiating this apoptotic effect were further investigated in vitro using the human androgen-independent To continue reading the complete article, login or register below and get free instant access.

The complete article is 1037 words long.

Login to Your Account Already have a TherapeuticsDaily.com or PharmaLive.com account?

Click on the button below to login.

Login to Your Account username : password : Remember me Free Access with Registration Access to TherapeuticsDaily.com is free for registered users.

To start the registration process, enter the fields below.

Email Zip Code Paid Advertisement TherapeuticsDaily.com is free with registration.

Created by PharmaLive.com, receive the best of therapeutic news directly into your E-mail box.

unsubscribe media kit ©2005 PharmaLive.co...

... Therapeutics Daily username : password : Remember me Newsletter Overviews Infectious Disease Article Preview U.S.

patent issued to Arius Research for anti-CD63 antibody for cancer treatment Women's Health Weekly - Apr.

06, 2006 Arius Research Inc.

(ARI) announced that it has received notice from the United States Patent and Trademark Office that U.S.

patent No.

7,009,040 was issued for Arius' lead anti-CD63 antibody, AR7BD-33-11A to treat cancer.

Previously Arius announced that it had received a Notice of Allowance in October 2005.

The patent covers the antibody molecule, various uses of the antibody, its derivatives, and a method for using it, and other similar antibodies, to treat cancers such as prostate and breast cancer.

Arius has several additional patent applications pending that will continue to enhance the value of this and other important ...

To continue reading the complete article, login or register below and get free instant access.

The complete article is 185 words long.

Login to Your Account Already have a TherapeuticsDaily.com or PharmaLive.com account?

Click on the button below to login.

Login to Your Account username : password : Remember me Free Access with Registration Access to TherapeuticsDaily.com is free for registered users.

To start the registration process, enter the fields below.

Email Zip Code Paid Advertiseme...